Health Catalyst, Inc. (HCAT) Stock Competitors & Peer Comparison
See (HCAT) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HCAT | $2.07 | +4.02% | 153M | 10.35 | $0.20 | N/A |
| VEEV | $184.22 | +3.80% | 29.9B | 22.12 | $8.33 | N/A |
| GEHC | $64.86 | +1.33% | 29.5B | 14.22 | $4.56 | +0.22% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| BTSGU | $229.79 | +0.37% | 13.8B | 208.78 | $1.11 | N/A |
| BTSG | $69.85 | +0.16% | 13.7B | 56.33 | $1.24 | N/A |
| TEM | $61.60 | +6.34% | 10.8B | -123.20 | -$0.50 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $92.29 | +2.18% | 7.7B | 21.56 | $4.28 | N/A |
| HNGE | $85.07 | +2.49% | 6.6B | 43.66 | $1.95 | N/A |
Stock Comparison
HCAT vs VEEV Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, VEEV has a market cap of 29.9B. Regarding current trading prices, HCAT is priced at $2.07, while VEEV trades at $184.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas VEEV's P/E ratio is 22.12. In terms of profitability, HCAT's ROE is -1.00%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, HCAT is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check VEEV's competition here
HCAT vs GEHC Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, GEHC has a market cap of 29.5B. Regarding current trading prices, HCAT is priced at $2.07, while GEHC trades at $64.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas GEHC's P/E ratio is 14.22. In terms of profitability, HCAT's ROE is -1.00%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, HCAT is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check GEHC's competition here
HCAT vs GEHCV Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, HCAT is priced at $2.07, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas GEHCV's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, HCAT is more volatile compared to GEHCV. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check GEHCV's competition here
HCAT vs BTSGU Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, BTSGU has a market cap of 13.8B. Regarding current trading prices, HCAT is priced at $2.07, while BTSGU trades at $229.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas BTSGU's P/E ratio is 208.78. In terms of profitability, HCAT's ROE is -1.00%, compared to BTSGU's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check BTSGU's competition here
HCAT vs BTSG Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, BTSG has a market cap of 13.7B. Regarding current trading prices, HCAT is priced at $2.07, while BTSG trades at $69.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas BTSG's P/E ratio is 56.33. In terms of profitability, HCAT's ROE is -1.00%, compared to BTSG's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check BTSG's competition here
HCAT vs TEM Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, TEM has a market cap of 10.8B. Regarding current trading prices, HCAT is priced at $2.07, while TEM trades at $61.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas TEM's P/E ratio is -123.20. In terms of profitability, HCAT's ROE is -1.00%, compared to TEM's ROE of -0.70%. Regarding short-term risk, HCAT is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check TEM's competition here
HCAT vs SGFY Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, HCAT is priced at $2.07, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas SGFY's P/E ratio is 70.91. In terms of profitability, HCAT's ROE is -1.00%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, HCAT is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check SGFY's competition here
HCAT vs HQY Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, HQY has a market cap of 7.7B. Regarding current trading prices, HCAT is priced at $2.07, while HQY trades at $92.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas HQY's P/E ratio is 21.56. In terms of profitability, HCAT's ROE is -1.00%, compared to HQY's ROE of +0.11%. Regarding short-term risk, HCAT is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check HQY's competition here
HCAT vs HNGE Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, HNGE has a market cap of 6.6B. Regarding current trading prices, HCAT is priced at $2.07, while HNGE trades at $85.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas HNGE's P/E ratio is 43.66. In terms of profitability, HCAT's ROE is -1.00%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, HCAT is more volatile compared to HNGE. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check HNGE's competition here
HCAT vs RCM Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, HCAT is priced at $2.07, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas RCM's P/E ratio is -102.21. In terms of profitability, HCAT's ROE is -1.00%, compared to RCM's ROE of +0.00%. Regarding short-term risk, HCAT is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check RCM's competition here
HCAT vs TXG Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, TXG has a market cap of 5B. Regarding current trading prices, HCAT is priced at $2.07, while TXG trades at $39.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas TXG's P/E ratio is -229.71. In terms of profitability, HCAT's ROE is -1.00%, compared to TXG's ROE of -0.03%. Regarding short-term risk, HCAT is more volatile compared to TXG. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check TXG's competition here
HCAT vs DOCS Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, DOCS has a market cap of 4B. Regarding current trading prices, HCAT is priced at $2.07, while DOCS trades at $21.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas DOCS's P/E ratio is 14.11. In terms of profitability, HCAT's ROE is -1.00%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, HCAT is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check DOCS's competition here
HCAT vs ONEM Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, HCAT is priced at $2.07, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas ONEM's P/E ratio is -7.77. In terms of profitability, HCAT's ROE is -1.00%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, HCAT is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check ONEM's competition here
HCAT vs PRVA Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, PRVA has a market cap of 3.4B. Regarding current trading prices, HCAT is priced at $2.07, while PRVA trades at $26.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas PRVA's P/E ratio is 168.00. In terms of profitability, HCAT's ROE is -1.00%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, HCAT is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check PRVA's competition here
HCAT vs HTFL Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, HTFL has a market cap of 2.6B. Regarding current trading prices, HCAT is priced at $2.07, while HTFL trades at $30.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas HTFL's P/E ratio is -15.28. In terms of profitability, HCAT's ROE is -1.00%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, HCAT is more volatile compared to HTFL. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check HTFL's competition here
HCAT vs PINC Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, HCAT is priced at $2.07, while PINC trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas PINC's P/E ratio is 19.22. In terms of profitability, HCAT's ROE is -1.00%, compared to PINC's ROE of -0.02%. Regarding short-term risk, HCAT is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check PINC's competition here
HCAT vs PGNY Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, PGNY has a market cap of 2.3B. Regarding current trading prices, HCAT is priced at $2.07, while PGNY trades at $29.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas PGNY's P/E ratio is 21.50. In terms of profitability, HCAT's ROE is -1.00%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, HCAT is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check PGNY's competition here
HCAT vs WGS Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, WGS has a market cap of 2.1B. Regarding current trading prices, HCAT is priced at $2.07, while WGS trades at $71.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas WGS's P/E ratio is 84.36. In terms of profitability, HCAT's ROE is -1.00%, compared to WGS's ROE of -0.28%. Regarding short-term risk, HCAT is more volatile compared to WGS. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check WGS's competition here
HCAT vs WGSWW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, WGSWW has a market cap of 1.8B. Regarding current trading prices, HCAT is priced at $2.07, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas WGSWW's P/E ratio is -0.09. In terms of profitability, HCAT's ROE is -1.00%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, HCAT is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check WGSWW's competition here
HCAT vs TDOC Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, TDOC has a market cap of 1.6B. Regarding current trading prices, HCAT is priced at $2.07, while TDOC trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas TDOC's P/E ratio is -10.11. In terms of profitability, HCAT's ROE is -1.00%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, HCAT is more volatile compared to TDOC. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check TDOC's competition here
HCAT vs NXGN Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, HCAT is priced at $2.07, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas NXGN's P/E ratio is -266.00. In terms of profitability, HCAT's ROE is -1.00%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, HCAT is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check NXGN's competition here
HCAT vs AGTI Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, HCAT is priced at $2.07, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas AGTI's P/E ratio is -71.79. In terms of profitability, HCAT's ROE is -1.00%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, HCAT is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check AGTI's competition here
HCAT vs OMDA Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, OMDA has a market cap of 1.3B. Regarding current trading prices, HCAT is priced at $2.07, while OMDA trades at $22.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas OMDA's P/E ratio is 323.14. In terms of profitability, HCAT's ROE is -1.00%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, HCAT is more volatile compared to OMDA. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check OMDA's competition here
HCAT vs NUTX Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, NUTX has a market cap of 1.1B. Regarding current trading prices, HCAT is priced at $2.07, while NUTX trades at $190.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas NUTX's P/E ratio is 14.74. In terms of profitability, HCAT's ROE is -1.00%, compared to NUTX's ROE of +0.31%. Regarding short-term risk, HCAT is more volatile compared to NUTX. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check NUTX's competition here
HCAT vs GDRX Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, GDRX has a market cap of 1.1B. Regarding current trading prices, HCAT is priced at $2.07, while GDRX trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas GDRX's P/E ratio is 9.27. In terms of profitability, HCAT's ROE is -1.00%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, HCAT is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check GDRX's competition here
HCAT vs CERT Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, CERT has a market cap of 1B. Regarding current trading prices, HCAT is priced at $2.07, while CERT trades at $6.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas CERT's P/E ratio is 17.26. In terms of profitability, HCAT's ROE is -1.00%, compared to CERT's ROE of -0.01%. Regarding short-term risk, HCAT is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check CERT's competition here
HCAT vs CCLDO Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, HCAT is priced at $2.07, while CCLDO trades at $27.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas CCLDO's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check CCLDO's competition here
HCAT vs HSTM Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, HSTM has a market cap of 826.2M. Regarding current trading prices, HCAT is priced at $2.07, while HSTM trades at $28.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas HSTM's P/E ratio is 37.21. In terms of profitability, HCAT's ROE is -1.00%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, HCAT is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check HSTM's competition here
HCAT vs PHR Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, PHR has a market cap of 663.2M. Regarding current trading prices, HCAT is priced at $2.07, while PHR trades at $10.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas PHR's P/E ratio is 38.32. In terms of profitability, HCAT's ROE is -1.00%, compared to PHR's ROE of +0.03%. Regarding short-term risk, HCAT is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check PHR's competition here
HCAT vs EVH Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, EVH has a market cap of 645.1M. Regarding current trading prices, HCAT is priced at $2.07, while EVH trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas EVH's P/E ratio is 573.50. In terms of profitability, HCAT's ROE is -1.00%, compared to EVH's ROE of -0.78%. Regarding short-term risk, HCAT is more volatile compared to EVH. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check EVH's competition here
HCAT vs MPLN-WT Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, HCAT is priced at $2.07, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, HCAT is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check MPLN-WT's competition here
HCAT vs ACCD Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, HCAT is priced at $2.07, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas ACCD's P/E ratio is -3.08. In terms of profitability, HCAT's ROE is -1.00%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, HCAT is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check ACCD's competition here
HCAT vs CCLDP Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, CCLDP has a market cap of 566.6M. Regarding current trading prices, HCAT is priced at $2.07, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas CCLDP's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check CCLDP's competition here
HCAT vs CTEV Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, CTEV has a market cap of 552.4M. Regarding current trading prices, HCAT is priced at $2.07, while CTEV trades at $32.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas CTEV's P/E ratio is -2.49. In terms of profitability, HCAT's ROE is -1.00%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, HCAT is more volatile compared to CTEV. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check CTEV's competition here
HCAT vs SHCR Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, HCAT is priced at $2.07, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas SHCR's P/E ratio is -3.76. In terms of profitability, HCAT's ROE is -1.00%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, HCAT is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check SHCR's competition here
HCAT vs NRC Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, NRC has a market cap of 503.5M. Regarding current trading prices, HCAT is priced at $2.07, while NRC trades at $22.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas NRC's P/E ratio is 25.39. In terms of profitability, HCAT's ROE is -1.00%, compared to NRC's ROE of +0.57%. Regarding short-term risk, HCAT is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check NRC's competition here
HCAT vs SLGCW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, HCAT is priced at $2.07, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, HCAT's ROE is -1.00%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, HCAT is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check SLGCW's competition here
HCAT vs SLGC Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, HCAT is priced at $2.07, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas SLGC's P/E ratio is -3.04. In terms of profitability, HCAT's ROE is -1.00%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, HCAT is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check SLGC's competition here
HCAT vs TBRG Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, TBRG has a market cap of 393.4M. Regarding current trading prices, HCAT is priced at $2.07, while TBRG trades at $26.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas TBRG's P/E ratio is 9.37. In terms of profitability, HCAT's ROE is -1.00%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, HCAT is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check TBRG's competition here
HCAT vs SOPH Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, SOPH has a market cap of 384.2M. Regarding current trading prices, HCAT is priced at $2.07, while SOPH trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas SOPH's P/E ratio is -10.75. In terms of profitability, HCAT's ROE is -1.00%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, HCAT is more volatile compared to SOPH. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check SOPH's competition here
HCAT vs MPLN Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, HCAT is priced at $2.07, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas MPLN's P/E ratio is -0.23. In terms of profitability, HCAT's ROE is -1.00%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, HCAT is more volatile compared to MPLN. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check MPLN's competition here
HCAT vs SLP Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, SLP has a market cap of 370.8M. Regarding current trading prices, HCAT is priced at $2.07, while SLP trades at $18.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas SLP's P/E ratio is 17.82. In terms of profitability, HCAT's ROE is -1.00%, compared to SLP's ROE of -0.49%. Regarding short-term risk, HCAT is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check SLP's competition here
HCAT vs TRHC Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, HCAT is priced at $2.07, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas TRHC's P/E ratio is -4.27. In terms of profitability, HCAT's ROE is -1.00%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, HCAT is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check TRHC's competition here
HCAT vs SMFR Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, HCAT is priced at $2.07, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas SMFR's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, HCAT is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check SMFR's competition here
HCAT vs SY Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, SY has a market cap of 223.1M. Regarding current trading prices, HCAT is priced at $2.07, while SY trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas SY's P/E ratio is -5.15. In terms of profitability, HCAT's ROE is -1.00%, compared to SY's ROE of -0.16%. Regarding short-term risk, HCAT is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check SY's competition here
HCAT vs SPOK Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, SPOK has a market cap of 220.8M. Regarding current trading prices, HCAT is priced at $2.07, while SPOK trades at $10.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas SPOK's P/E ratio is 17.62. In terms of profitability, HCAT's ROE is -1.00%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, HCAT is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check SPOK's competition here
HCAT vs AMWL Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, AMWL has a market cap of 157.1M. Regarding current trading prices, HCAT is priced at $2.07, while AMWL trades at $9.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas AMWL's P/E ratio is -1.81. In terms of profitability, HCAT's ROE is -1.00%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, HCAT is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check AMWL's competition here
HCAT vs CPSI Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, HCAT is priced at $2.07, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas CPSI's P/E ratio is -183.80. In terms of profitability, HCAT's ROE is -1.00%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, HCAT is more volatile compared to CPSI. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check CPSI's competition here
HCAT vs AUGX Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, HCAT is priced at $2.07, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas AUGX's P/E ratio is -4.99. In terms of profitability, HCAT's ROE is -1.00%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, HCAT is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check AUGX's competition here
HCAT vs OPRX Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, OPRX has a market cap of 114.1M. Regarding current trading prices, HCAT is priced at $2.07, while OPRX trades at $6.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas OPRX's P/E ratio is 5.58. In terms of profitability, HCAT's ROE is -1.00%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, HCAT is more volatile compared to OPRX. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check OPRX's competition here
HCAT vs CCLD Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, CCLD has a market cap of 96.5M. Regarding current trading prices, HCAT is priced at $2.07, while CCLD trades at $2.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas CCLD's P/E ratio is 6.88. In terms of profitability, HCAT's ROE is -1.00%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, HCAT is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check CCLD's competition here
HCAT vs DH Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, DH has a market cap of 84.4M. Regarding current trading prices, HCAT is priced at $2.07, while DH trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas DH's P/E ratio is 3.08. In terms of profitability, HCAT's ROE is -1.00%, compared to DH's ROE of -0.67%. Regarding short-term risk, HCAT is more volatile compared to DH. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check DH's competition here
HCAT vs FORA Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, HCAT is priced at $2.07, while FORA trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas FORA's P/E ratio is -24.11. In terms of profitability, HCAT's ROE is -1.00%, compared to FORA's ROE of -0.17%. Regarding short-term risk, HCAT is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check FORA's competition here
HCAT vs ONMD Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, ONMD has a market cap of 39.7M. Regarding current trading prices, HCAT is priced at $2.07, while ONMD trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas ONMD's P/E ratio is -4.86. In terms of profitability, HCAT's ROE is -1.00%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, HCAT is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check ONMD's competition here
HCAT vs SNCE Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, HCAT is priced at $2.07, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas SNCE's P/E ratio is -0.27. In terms of profitability, HCAT's ROE is -1.00%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, HCAT is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check SNCE's competition here
HCAT vs AKLI Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, HCAT is priced at $2.07, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas AKLI's P/E ratio is -0.71. In terms of profitability, HCAT's ROE is -1.00%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, HCAT is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check AKLI's competition here
HCAT vs SHLT Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, HCAT is priced at $2.07, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas SHLT's P/E ratio is -3.87. In terms of profitability, HCAT's ROE is -1.00%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, HCAT is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check SHLT's competition here
HCAT vs SHCRW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, HCAT is priced at $2.07, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, HCAT's ROE is -1.00%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, HCAT is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check SHCRW's competition here
HCAT vs ONMDW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, ONMDW has a market cap of 31.4M. Regarding current trading prices, HCAT is priced at $2.07, while ONMDW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas ONMDW's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, HCAT is more volatile compared to ONMDW. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check ONMDW's competition here
HCAT vs EUDA Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, EUDA has a market cap of 28M. Regarding current trading prices, HCAT is priced at $2.07, while EUDA trades at $14.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas EUDA's P/E ratio is -2.75. In terms of profitability, HCAT's ROE is -1.00%, compared to EUDA's ROE of +0.13%. Regarding short-term risk, HCAT is more volatile compared to EUDA. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check EUDA's competition here
HCAT vs STRM Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, HCAT is priced at $2.07, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas STRM's P/E ratio is -2.40. In terms of profitability, HCAT's ROE is -1.00%, compared to STRM's ROE of -0.32%. Regarding short-term risk, HCAT is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check STRM's competition here
HCAT vs RNLX Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, HCAT is priced at $2.07, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas RNLX's P/E ratio is -0.33. In terms of profitability, HCAT's ROE is -1.00%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, HCAT is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check RNLX's competition here
HCAT vs LIFW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, HCAT is priced at $2.07, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas LIFW's P/E ratio is -0.02. In terms of profitability, HCAT's ROE is -1.00%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, HCAT is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check LIFW's competition here
HCAT vs BEATW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, BEATW has a market cap of 20.4M. Regarding current trading prices, HCAT is priced at $2.07, while BEATW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas BEATW's P/E ratio is -0.06. In terms of profitability, HCAT's ROE is -1.00%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, HCAT is more volatile compared to BEATW. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check BEATW's competition here
HCAT vs BBLN Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, HCAT is priced at $2.07, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas BBLN's P/E ratio is -0.04. In terms of profitability, HCAT's ROE is -1.00%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, HCAT is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check BBLN's competition here
HCAT vs ETAO Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, HCAT is priced at $2.07, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas ETAO's P/E ratio is -0.01. In terms of profitability, HCAT's ROE is -1.00%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, HCAT is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check ETAO's competition here
HCAT vs BFRG Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, BFRG has a market cap of 8.3M. Regarding current trading prices, HCAT is priced at $2.07, while BFRG trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas BFRG's P/E ratio is -1.31. In terms of profitability, HCAT's ROE is -1.00%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, HCAT is more volatile compared to BFRG. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check BFRG's competition here
HCAT vs HLTH Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, HCAT is priced at $2.07, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas HLTH's P/E ratio is -0.02. In terms of profitability, HCAT's ROE is -1.00%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, HCAT is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check HLTH's competition here
HCAT vs SCNX Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, SCNX has a market cap of 5.5M. Regarding current trading prices, HCAT is priced at $2.07, while SCNX trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas SCNX's P/E ratio is -0.14. In terms of profitability, HCAT's ROE is -1.00%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, HCAT is more volatile compared to SCNX. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check SCNX's competition here
HCAT vs UPH-WT Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, HCAT is priced at $2.07, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, HCAT is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check UPH-WT's competition here
HCAT vs UPH Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, HCAT is priced at $2.07, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas UPH's P/E ratio is -0.07. In terms of profitability, HCAT's ROE is -1.00%, compared to UPH's ROE of -1.05%. Regarding short-term risk, HCAT is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check UPH's competition here
HCAT vs MGRX Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, MGRX has a market cap of 4.3M. Regarding current trading prices, HCAT is priced at $2.07, while MGRX trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas MGRX's P/E ratio is -0.31. In terms of profitability, HCAT's ROE is -1.00%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, HCAT is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check MGRX's competition here
HCAT vs PEAR Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, HCAT is priced at $2.07, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas PEAR's P/E ratio is -0.08. In terms of profitability, HCAT's ROE is -1.00%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, HCAT is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check PEAR's competition here
HCAT vs PEARW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, HCAT is priced at $2.07, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas PEARW's P/E ratio is -0.00. In terms of profitability, HCAT's ROE is -1.00%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, HCAT is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check PEARW's competition here
HCAT vs OTRK Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, HCAT is priced at $2.07, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas OTRK's P/E ratio is -0.02. In terms of profitability, HCAT's ROE is -1.00%, compared to OTRK's ROE of -1.66%. Regarding short-term risk, HCAT is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check OTRK's competition here
HCAT vs HCTI Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, HCTI has a market cap of 2.2M. Regarding current trading prices, HCAT is priced at $2.07, while HCTI trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas HCTI's P/E ratio is -0.02. In terms of profitability, HCAT's ROE is -1.00%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, HCAT is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check HCTI's competition here
HCAT vs VSEE Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, VSEE has a market cap of 1.9M. Regarding current trading prices, HCAT is priced at $2.07, while VSEE trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas VSEE's P/E ratio is -0.22. In terms of profitability, HCAT's ROE is -1.00%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, HCAT is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check VSEE's competition here
HCAT vs ACON Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, ACON has a market cap of 1.6M. Regarding current trading prices, HCAT is priced at $2.07, while ACON trades at $3.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas ACON's P/E ratio is -0.29. In terms of profitability, HCAT's ROE is -1.00%, compared to ACON's ROE of -0.54%. Regarding short-term risk, HCAT is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check ACON's competition here
HCAT vs CMAX Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, HCAT is priced at $2.07, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas CMAX's P/E ratio is -0.00. In terms of profitability, HCAT's ROE is -1.00%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, HCAT is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check CMAX's competition here
HCAT vs BFRGW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, BFRGW has a market cap of 1.5M. Regarding current trading prices, HCAT is priced at $2.07, while BFRGW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas BFRGW's P/E ratio is -1.00. In terms of profitability, HCAT's ROE is -1.00%, compared to BFRGW's ROE of -2.18%. Regarding short-term risk, HCAT is more volatile compared to BFRGW. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check BFRGW's competition here
HCAT vs VSEEW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, VSEEW has a market cap of 1.5M. Regarding current trading prices, HCAT is priced at $2.07, while VSEEW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas VSEEW's P/E ratio is -0.06. In terms of profitability, HCAT's ROE is -1.00%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, HCAT is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check VSEEW's competition here
HCAT vs LIFWZ Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, HCAT is priced at $2.07, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, HCAT is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check LIFWZ's competition here
HCAT vs EUDAW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, EUDAW has a market cap of 1M. Regarding current trading prices, HCAT is priced at $2.07, while EUDAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas EUDAW's P/E ratio is 0.03. In terms of profitability, HCAT's ROE is -1.00%, compared to EUDAW's ROE of +0.13%. Regarding short-term risk, HCAT is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check EUDAW's competition here
HCAT vs MSPRZ Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, HCAT is priced at $2.07, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, HCAT is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check MSPRZ's competition here
HCAT vs WORX Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, WORX has a market cap of 303.5K. Regarding current trading prices, HCAT is priced at $2.07, while WORX trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas WORX's P/E ratio is -1.17. In terms of profitability, HCAT's ROE is -1.00%, compared to WORX's ROE of -0.65%. Regarding short-term risk, HCAT is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check WORX's competition here
HCAT vs KERNW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, HCAT is priced at $2.07, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas KERNW's P/E ratio is -0.00. In terms of profitability, HCAT's ROE is -1.00%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, HCAT is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check KERNW's competition here
HCAT vs KERN Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, HCAT is priced at $2.07, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas KERN's P/E ratio is -0.01. In terms of profitability, HCAT's ROE is -1.00%, compared to KERN's ROE of -0.17%. Regarding short-term risk, HCAT is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check KERN's competition here
HCAT vs LIFWW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, HCAT is priced at $2.07, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas LIFWW's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, HCAT is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check LIFWW's competition here
HCAT vs ZCMD Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, ZCMD has a market cap of 38.9K. Regarding current trading prices, HCAT is priced at $2.07, while ZCMD trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas ZCMD's P/E ratio is -0.04. In terms of profitability, HCAT's ROE is -1.00%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, HCAT is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check ZCMD's competition here
HCAT vs CMAXW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, HCAT is priced at $2.07, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas CMAXW's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, HCAT is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check CMAXW's competition here
HCAT vs ACONW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, ACONW has a market cap of 13.2K. Regarding current trading prices, HCAT is priced at $2.07, while ACONW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas ACONW's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to ACONW's ROE of -0.54%. Regarding short-term risk, HCAT is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check ACONW's competition here
HCAT vs NAVA Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, NAVA has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.07, while NAVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas NAVA's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, Volatility data is not available for a full comparison. HCAT has daily volatility of 12.32 and NAVA has daily volatility of N/A.Check NAVA's competition here
HCAT vs AFFX Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, AFFX has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.07, while AFFX trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas AFFX's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, HCAT is more volatile compared to AFFX. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check AFFX's competition here
HCAT vs CHNGU Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.07, while CHNGU trades at $73.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas CHNGU's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, HCAT is more volatile compared to CHNGU. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check CHNGU's competition here
HCAT vs MTBC Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.07, while MTBC trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas MTBC's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to MTBC's ROE of +0.17%. Regarding short-term risk, HCAT is less volatile compared to MTBC. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check MTBC's competition here
HCAT vs CERN Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, CERN has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.07, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas CERN's P/E ratio is 55.84. In terms of profitability, HCAT's ROE is -1.00%, compared to CERN's ROE of +0.14%. Regarding short-term risk, HCAT is more volatile compared to CERN. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check CERN's competition here
HCAT vs CHNG Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.07, while CHNG trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas CHNG's P/E ratio is -152.72. In terms of profitability, HCAT's ROE is -1.00%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, HCAT is more volatile compared to CHNG. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check CHNG's competition here
HCAT vs KURIU Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, KURIU has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.07, while KURIU trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas KURIU's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to KURIU's ROE of +1.06%. Regarding short-term risk, HCAT is more volatile compared to KURIU. This indicates potentially higher risk in terms of short-term price fluctuations for HCAT.Check KURIU's competition here
HCAT vs SMFRW Comparison July 2026
HCAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCAT stands at 153M. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, HCAT is priced at $2.07, while SMFRW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCAT currently has a P/E ratio of 10.35, whereas SMFRW's P/E ratio is N/A. In terms of profitability, HCAT's ROE is -1.00%, compared to SMFRW's ROE of -0.28%. Regarding short-term risk, HCAT is less volatile compared to SMFRW. This indicates potentially lower risk in terms of short-term price fluctuations for HCAT.Check SMFRW's competition here